Delving into the Latest Updates on Recombinant Covid-19 vaccine (Shenzhen Kangtai) with Synapse

Overview

Basic Info

Drug Type

Recombinant vector vaccine, Prophylactic vaccine

Synonyms

KconecaVac

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

COVID-19

Inactive Indication-

Originator Organization

Shenzhen Kangtai Biological Products Co., Ltd.

Active Organization

Shenzhen Kangtai Biological Products Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

Indonesia (03 Nov 2021),

COVID-19

RegulationEmergency Use Authorization (Indonesia)

Login to view timeline

This data article is related to the previous research, which addressed the development of a COVID-19 recombinant vaccine candidate. Here, we present the additional data in support of the safety and protective efficacy evaluation of two COVID-19 vaccine candidates based on the coronaviruses' S protein fragments and a structurally modified plant virus - spherical particles. The effectiveness of the experimental vaccines was studied against the SARS-CoV-2 virus in an in vivo infection model in female Syrian hamsters. The body weight of vaccinated laboratory animals was monitored. The histological assessment data of the infected with the SARS-CoV-2 virus hamsters' lungs are provided.

100 Deals associated with Recombinant Covid-19 vaccine (Shenzhen Kangtai)

Login to view more data